Delivery Order SPE2DB24D2106-SPE2DB24FAUPT

Award Date 7/30/24
Potential Completion Date 7/31/24
Potential Value $8.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,059.74 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes. The award is not associated with any set-aside designation. The contract is part of DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to issue delivery...
This is a firm fixed-price delivery order award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of 4,567,721,071 units of the pharmaceutical product STELARA 90 MG/ML SYRINGE. The award is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,640.32 firm fixed-price delivery order is for the supply of Stelara 90 mg/ml syringes, a specialized injectable medication. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA to issue delivery orders...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,662.04 firm fixed-price delivery order contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This federal contract award is a delivery order valued at $4,974.08, issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract provides for the delivery of STELARA 130 MG/26 ML VIAL 26ML, a biologic medication. The order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which allows the DLA to issue firm fixed-price delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,538.62 award is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical needs of the Department of Defense (DoD). This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,220.68 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of STELARA 130 MG/26 ML VIAL 26ML. The contract has a ceiling value of $4,974.08 and an ultimate completion date of July 25, 2024. The contract is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, with no set-aside designation. This contract award is part of a larger indefinite delivery contract (IDC) valued...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of the drug Stelara 90 mg/ml syringe. The award, valued at $7,108.82, has a period of performance through May 10, 2024. This delivery order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999, which allows the DLA to issue firm fixed-price orders for a wide...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,441.36 firm fixed-price delivery order is for the provision of STELARA 90 MG/ML SYRINGE pharmaceutical products. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB24FAUPT
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,611.25 firm fixed-price delivery order is for the supply of the drug STELARA 90 MG/ML SYRINGEML. The award is not a set-aside contract.

The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and specialized medications to the Department of Defense healthcare system.

Generated 10/29/24, 9:04 AM